Page 62 - Read Online

Genvigir et al. J Transl Genet Genom 2020;4:320-55 I http://dx.doi.org/10.20517/jtgg.2020.37 Page 347

Ref. [22] [75] [25] [71] [78] [72] [80] [73] [29]

Clinical outcomes No association of IMPDH1 variant with IMPDH1 rs2278294 G allele was associated with slower BMI gain IMPDH2 3757C allele was associated with increased risk of AR No association of IMPDH2 variants with AR or leukopenia IMPDH2 3757C allele was associated with increased MPA plasma concentration (6 h after MMF intake) and increased IMPDH activity in PBMC (12 h after MMF intake) No association of IMPDH2 variant with No associa

Immunosuppressive regimen AR Cyclosporine Tacrolimus One-year follow-up Five-year follow-up One-year follow-up One-year follow-up One-year follow-up AR One-year follow-up Calcineurin inhibitors One-year follow-up One-year follow-up Six-month follow-up

MMF Sirolimus Corticosteroids MMF Cyclosporine Tacrolimus Corticosteroids MMF Cyclosporine Corticosteroids MMF Tacrolimus Prednisone MMF Tacrolimus Corticosteroids MMF Cyclosporine Tacrolimus Corticosteroids MMF Corticosteroids MMF Cyclosporine Tacrolimus Corticosteroids EC-MPS Cyclosporine Corticosteroids

145 adult patients (Brazil) 190 adult patients (Poland) 237 adult patients 191 adult patients (USA) 101 adult patients (Netherlands) 456 adult patients 177 adult patients (Poland) 1,040 adult patients 189 adult patients

Population

Study design Prospective, multicenter Prospective (Apomygre and Prospective, multicenter (Collaborative Transplant Prospective, multicenter

Retrospective (Case-control) Prospective (CAESAR study) Retrospective Prospective FDCC studies) Prospective study) (Dominos study)

Allele frequency rs2278293 A: 47% rs2278293 A: 45% rs2278294 A: 30% 3757C: 7% 3757TC+CC: 9% c.787T: 0.3% 3757C: 7% rs11706052 C: 9% rs4974081 G: 24% 3757C: 8% rs11706052 G: 19% rs11706052 C: 11%

rs11706052 A>G (c.819+10T>C, also known as 3757T>C) rs121434586 (Leu236Phe, c.787C>T) rs4974081 (-3624A>G)
Variant

Gene IMPDH2